SAN DIEGO -- Accelrys Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (NASDAQ:PCOP), today announced plans to release Insight II(R) and Catalyst(R), Accelrys' premiere modeling and simulation software suites, for the Linux operating system. Accelrys will collaborate with IBM to complete the porting and certify the products on the latest IBM IntelliStation(R) workstations running Red Hat Linux. These new versions will allow researchers to take advantage of the stability, speed and graphical capabilities of stand-alone Linux workstations, also giving them the choice to add IBM eServer(TM) systems running either Linux or IBM AIX(R) for compute-intensive calculations. The products are expected to be commercially available by December 2003, and Accelrys plans to distribute full software/hardware solution packages on certified IBM configurations. "Our pharmaceutical and biotech customers are interested in emerging platforms that provide the best price performance. We are fully committed to supporting researchers by providing them with the most advanced and capable drug discovery and development applications on the platforms that best suit their interests," said Mark Emkjer, president, Accelrys. "IBM's Linux expertise will help ensure that the software and hardware quality is state-of-the-art." "The momentum for Linux solutions continues to grow in life sciences," said Mike Svinte, vice president, worldwide marketing and business development, IBM Life Sciences. "Through our global Strategic Alliance, IBM and Accelrys will combine resources, technologies and expertise to deliver advanced Linux-based research tools that can help our mutual customers address their business needs."